Lasa Supergenerics Ltd

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 23 Jan 2026, hitting its lower circuit limit and registering a maximum daily loss of 2.55%. The stock’s sharp decline reflects mounting investor concerns amid deteriorating technical and fundamental indicators.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in buying interest on 22 Jan 2026, hitting its upper circuit price limit. Despite recent underperformance relative to its sector and broader market indices, the stock’s sudden rally underscores intense demand and a potential shift in investor sentiment.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 14 Jan 2026, hitting its lower circuit limit amid intense selling pressure. The stock closed at ₹9.43, down 4.46% on the day, marking its fifth consecutive day of losses and signalling mounting investor concerns.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 12 Jan 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The share price plunged by nearly 5%, marking its maximum daily loss and signalling panic selling among investors amid subdued market sentiment.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 9 Jan 2026, hitting its lower circuit limit and registering a maximum daily loss of 4.8%. The stock’s sharp decline reflects mounting investor concerns amid falling participation and unfilled supply, signalling a period of heightened volatility and bearish sentiment.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 07 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Lasa Supergenerics Ltd surged to hit its upper circuit limit on 7 Jan 2026, propelled by robust buying interest and a maximum daily gain of 4.18%. The stock’s performance outpaced its sector and broader market indices, reflecting heightened investor enthusiasm despite a micro-cap market capitalisation of ₹59.37 crore and a recent downgrade to a Strong Sell rating by MarketsMOJO.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 2 January 2026, registering a maximum daily gain of 9.92%. This sharp rally was driven by strong buying interest, a significant rise in delivery volumes, and a notable gap-up opening, signalling renewed investor confidence despite the company’s recent downgrade to a Strong Sell rating by MarketsMOJO.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 1 Jan 2026, propelled by robust buying interest and a notable 8.47% intraday price gain. The stock’s performance outpaced its sector and benchmark indices, reflecting heightened investor enthusiasm despite its current strong sell rating.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 26 December 2025, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.

Lasa Supergeneri, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation metrics. This shift reflects recent developments across multiple analytical parameters, highlighting ongoing challenges in the company’s financial and operational performance.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 24 Nov 2025 as it hit its lower circuit limit, reflecting intense selling pressure and a significant daily loss that outpaced both its sector and the broader market indices.

Lasa Supergenerics Ltd has encountered significant selling pressure, with the stock registering a sharp decline of 4.91% today and exhibiting a complete absence of buyers. This extreme selling activity reflects distress signals as the pharmaceutical company continues to underperform against broader market indices and its sector peers.

Lasa Supergenerics Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, reached its upper circuit limit today, with a notable increase in investor participation. The stock's trading volume surged significantly, reflecting strong market activity despite being below its moving averages across various time frames.